Current Report Filing (8-k)
March 30 2020 - 8:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 30, 2020
_______________________________
PROTEO, INC.
(Exact name of registrant as specified in
its charter)
_______________________________
Nevada
|
000-30728
|
90-0019065
|
(State or Other Jurisdiction
|
(Commission
|
(I.R.S. Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
2102 Business Center Drive, Irvine, California
92612
(Address of Principal Executive Offices)
(Zip Code)
(949) 253-4155
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each Class
|
Trading Symbol
|
Name of each exchange on which registered
|
None
|
None
|
None
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b 2 of this chapter).
Emerging growth company ☐
If any emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
|
(a)
|
On March 4, 2020, the U.S. Securities and Exchange Commission (the "Commission") issued
an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as
amended ("Exchange Act"), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder
(the "Order"). The Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a)
or 15(d), and any person required to make any filings with respect to such a registrant, is exempt from any requirement to file
or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations
13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C
and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, where certain conditions are satisfied.
|
Proteo, Inc. (the "Company")
is furnishing this Current Report on Form 8-K to indicate its reliance on the Order in connection with the Company's Annual Report
on Form 10-K for the year ended December 31, 2019 as a result of the circumstances set forth below.
After the diagnosis of COVID-19
virus for one of the Company employees, the Company has closed its corporate offices and has requested all employees to work remotely
until further notice. Employees affected by such closure include certain of its key personnel responsible for assisting the Company
in the preparation of its financial statements. In view of these circumstances, the Company has been unable to timely provide its
auditors and accountants with financial records to provide consent, and therefore allow the Company to file a timely and accurate
Annual Report on Form 10-K for its year ended December 31, 2019 by the prescribed date without undue hardship and expense to the
Company.
Accordingly, in reliance upon
the Order, the Company expects to file its Annual Report on Form 10-K no later than 45 days after March 30, 2020.
The Company is adding to the
Company's Annual Report on Form 10-K for the year ended December 31, 2018 and its subsequent Quarterly Reports on Form 10-Q the
following risk factor:
Our business may suffer from the
severity or longevity of the Coronavirus/COVID-19 Global Outbreak. The Coronavirus ("Covid-19") is currently impacting
countries, communities, supply chains and markets, as well as the global financial markets. To date, Covid-19 has not had a material
impact on the Company, other than as set forth above. However, the Company cannot predict whether Covid-19 will have a material
impact on our financial condition and results of operations due to understaffing, disruptions in government spending, among other
factors. In addition, at this time we cannot predict the impact of Covid-19 on our ability to obtain financing necessary for the
Company to fund its working capital requirements. In most respects, it is too early in the Covid-19 pandemic to be able to quantify
or qualify the longer-term ramifications on our business and/or our potential investors.
|
(b)
|
The Company is a clinical stage drug development company and has historically relied on government
grant funds, as well as proceeds from the sales of the Company’s common and preferred stock, in order to fund its operations.
The Company does not expect any further funding under its current grant from the German State of Schleswig-Holstein after the scheduled
expiry in the end of April 2020. Due to recent developments, including the impact of the COVID-19 outbreak and disruptions in government
spending, the Company is unlikely to receive funding under a new grant. Further, the Company no longer expects to receive further
funding pursuant to its current agreement with one of its preferred stockholders. At this time, we cannot predict the impact of
Covid-19 on our ability to obtain financing necessary for the Company to fund our working capital requirements. As a result, the
Company’s management and the board of directors are currently exploring strategic alternatives in order to meet its operating
cash flow requirements. However, there are no assurances that the Company will be successful in implementing a strategic plan in
order to address its impending liquidity constraints. These conditions, among others, raise substantial doubt about the Company’s
ability to continue as a going concern.
|
Cautionary Note Regarding Forward-Looking Statements.
This Current Report on Form 8-K contains
statements as to the Company's beliefs and expectations of the outcome of future events that are forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not
relate strictly to historical or current facts. Examples of these statements include, but are not limited to, statements regarding
the anticipated impact of the COVID-19 outbreak on travel and physical locations, the anticipated impact of such outbreak on our
results of operations, and possible effect of the postponement and cancellation of trade shows and events on our overall revenues.
These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from
the statements made. These risks and uncertainties include, but are not limited to, the effects of the COVID- 19 outbreak, including
on our business activities (including our evaluation of the Company options and if the Company will be able to continue as a going
concern if no additional funding is secured in the near term) and levels of business and economic confidence generally. The duration
of the COVID-19 outbreak and severity of such outbreak, the pace of recovery following the COVID-19 outbreak, the effect on our
ability to implement cost containment and business restructuring strategies; and the adverse effects of the COVID-19 outbreak on
our business and the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2018 and our subsequent
filings with the U.S. Securities and Exchange Commission, including subsequent quarterly reports on Forms 10-Q and current reports
on Form 8-K are uncertain. Except as required by law, the Company does not undertake any obligation to release publicly any revisions
to forward-looking statements made by it to reflect events or circumstances occurring after the date hereof or the occurrence of
unanticipated events.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
Proteo, Inc.
|
|
|
|
By
|
/s/ Oliver Wiedow
|
|
|
Name: Oliver Wiedow
Title: Chief Executive Officer and Chief Financial Officer
|
Date: March 30,
2020
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From May 2024 to Jun 2024
Proteo (GM) (USOTC:PTEO)
Historical Stock Chart
From Jun 2023 to Jun 2024